Connect to electronic resource

Table of Contents “...The Use of Projective Tests in Assessing Neurologically Impaired Populations /...”

Table of Contents

Table of Contents “...Machine generated contents note: 1.1.Antiquity -- 1.2.Middle Ages -- 1.3.Modern Era -- References -- 2.1.Normal Emotions, Neurobiology and Ethological Considerations -- 2.2.The Conceptualization of Bipolar Disorder -- 2.3.Bipolar Depression -- 2.4.Mania -- 2.5.Hypomania -- 2.6.Mixed States -- 2.7.Psychotic Features -- 2.8.Other Clinical Issues -- 2.9.The Subjective Experience of Manic[—]Depressive Patients -- 2.10.List and Definitions of Symptoms and Signs -- 2.10.1.Mood -- 2.10.2.Psychomotor Disorder -- 2.10.3.Neurocognitive Disorder -- 2.10.4.Thought Disorder -- 2.10.5.Psychotic Features -- 2.10.6.Somatic and Neurovegetative Symptoms -- 2.10.7.Behavioural Disorder -- References -- 3.1.Predominant Polarity -- 3.2.Seasonality -- 3.3.Rapid Cycling -- References -- 4.1.General Neurocognitive Functioning and Intelligence Quotient (IQ) -- 4.2.Psychomotor and Mental Speed -- 4.3.Attention -- 4.4.Learning and Memory -- 4.5.Verbal Skills -- 4.6.Visuospatial Skills -- 4.7.Executive Function -- 4.8.Social Cognition and Theory of Mind (ToM) -- 4.8.1.ToM -- 4.8.2.Emotion Processing -- 4.8.3.Emotional Decision-Making -- 4.8.4.Reviews and Meta-analyses -- 4.9.Clinical Correlations -- 4.9.1.The Effect of Medication -- 4.9.2.The Effect of Psychotic Symptoms -- 4.9.3.The Effect of Mood Symptoms -- 4.9.4.The Effect of Age and Age at Onset and Personal Psychiatric History -- 4.9.5.The Role of Other Clinical Factors -- 4.10.BD-II -- 4.11.Long-Term Development of the Neurocognitive Deficit -- 4.12.Awareness of the Neurocognitive Deficit -- 4.13.Gender and the Neurocognitive Deficit -- 4.14.The Neurocognitive Deficit as an Endophenotype for BD -- 4.14.1.Twin Studies -- 4.14.2.Studies on First-Degree Relatives -- 4.14.3.Studies on Mixed Samples of Relatives -- 4.14.4.Reviews and Meta-analyses -- References -- 5.1.Historical Perspective -- References -- References -- References -- References -- 9.1.Epidemiology -- 9.1.1.Epidemiology of Alcohol Use Disorder -- 9.1.2.Epidemiology of Cannabis Use Disorder -- 9.1.3.Epidemiology of Gambling -- 9.1.4.Epidemiology of Methadone -- 9.1.5.Epidemiology of Cocaine -- 9.1.6.Epidemiology of Opioids -- 9.1.7.Epidemiology of Smoking -- 9.2.Etiopathogenesis of SUD in BD -- 9.2.1.General Causative Factors and Mechanisms -- 9.2.2.Neurobiology -- 9.3.Clinical Issues -- 9.3.1.Clinical Issues Related to Alcohol Use -- 9.3.2.Clinical Issues Related to Cannabis Use -- 9.3.3.Clinical Issues Related to Cocaine Use -- 9.3.4.Clinical Issues Related to Opioid Use -- 9.3.5.Clinical Issues Related to Nicotine Use and Smoking -- 9.3.6.Substance Use and Neurocognitive Disorder -- 9.3.7.Comorbidity -- 9.3.8.Disability -- 9.3.9.Suicidality -- 9.4.Legal Issues -- 9.5.Treatment -- References -- 10.1.Psychiatric Comorbidity -- 10.1.1.Comorbid Anxiety -- 10.1.2.Comorbid Obsessive[—]Compulsive Disorder (OCD) -- 10.1.3.Comorbid Attention Deficit Hyperactivity Disorder (ADHD) -- 10.1.4.Comorbid Complicated Grief (CG) -- 10.1.5.Comorbid Eating Disorders -- 10.1.6.Various Other Comorbid Conditions -- 10.1.7.Comorbid Psychiatric Disorders and BD-II -- 10.2.Medical Comorbidity -- 10.2.1.General Medical Comorbidity -- 10.2.2.Metabolic Syndrome and Related Medical Conditions -- 10.2.3.Comorbid Vascular Disease -- 10.2.4.Comorbid Neurological Conditions -- 10.2.5.Infectious Diseases -- 10.2.6.Cancer -- 10.2.7.Endocrinological Disorders -- 10.2.8.Gastroenterological Disorders -- 10.2.9.Disorders of the Blood -- 10.2.10.Respiratory System Disorders -- 10.2.11.Various Comorbid Medical Disorders -- 10.3.Genetics and Endophenotypes -- References -- 11.1.Classification -- 11.1.1.General Considerations -- 11.1.2.Contemporary Classification Systems -- 11.1.3.Contemporary Classification of BD and Related Disorders -- 11.2.Epidemiology of BD -- 11.2.1.The Amish Study -- 11.2.2.The Epidemiological Catchment Area (ECA) -- 11.2.3.The National Comorbidity Survey (NCS) -- 11.2.4.The Cross-National Collaborative Group (CNCG) -- 11.2.5.Zurich Switzerland -- 11.2.6.Shatin, Hong Kong -- 11.2.7.Nottingham, UK -- 11.2.8.The Netherlands Study -- 11.2.9.The Australian Study -- 11.2.10.The Butajira Study -- 11.2.11.The Merikangas Study -- 11.2.12.Other Smaller Studies -- 11.2.13.Epidemiology of the Bipolar Spectrum -- 11.2.14.Conclusions on Epidemiology -- References -- 12.1.Disability -- 12.1.1.Overview and Definitions -- 12.1.2.Disability in BD Patients -- 12.2.Quality of Life -- 12.3.Caregiver and Family Burden -- 12.3.1.Prevalence of Caregiver Burden -- 12.3.2.Objective Burden -- 12.3.3.Subjective Burden -- 12.3.4.Influence of Sociodemographic Factors on Caregiver Burden -- 12.3.5.Special Topics Related to Caregiver Burden -- 12.3.6.Comparison with Burden Caused by Other Disorders -- 12.3.7.Interventions -- 12.3.8.Caregiver Burden and Patient Outcome -- 12.4.Cost -- 12.5.Stigma -- References -- 13.1.Social Theories -- 13.2.Psychological Theories -- 13.2.1.Aggression-Turned-Inward Model -- 13.2.2.Object Loss -- 13.2.3.Loss of Self-Esteem -- 13.2.4.Cognitive Model -- 13.2.5.Learned Helplessness Model -- 13.2.6.Depression and Reinforcement -- 13.3.Neurobiology of BD -- 13.3.1.Neuroanatomy of BD -- 13.3.2.Functional Studies -- 13.3.3.Neurotransmitters and Receptors -- 13.3.4.Genetic Studies -- References -- 14.1.Introduction -- 14.2.Psychometric Tools -- 14.2.1.Depression Rating Scales -- 14.2.2.Mania Rating Scales -- 14.2.3.Anxiety Rating Scales -- 14.2.4.Psychotic Symptoms Rating Scales -- 14.2.5.Disability and General Assessment -- 14.2.6.Temperament and Personality Inventories -- 14.2.7.Adverse Events Scales -- 14.2.8.Substance Use Scales -- 14.2.9.Other Rating Scales -- 14.3.Neuropsychological Tools -- References -- 15.1.The Concept of Staging -- 15.2.Staging of BD -- 15.2.1.Clinical Determinants of BD Staging -- 15.2.2.Neurobiological Determinants of BD Staging -- 15.2.3.Treatment Data Supporting the Staging Approach -- 15.3.Existing Models for the Staging of BD -- 15.3.1.The Model of Berk -- 15.3.2.The Model of Kapczinski -- 15.3.3.The Model of Post -- 15.3.4.The Model of Cosci and Fava -- 15.3.5.The Model of Frank -- 15.4.The Future of Staging of BD -- References -- 16.1.General Background -- 16.1.1.Lithium -- 16.1.2.Antiepileptics -- 16.1.3.Antipsychotics -- 16.1.4.Antidepressants -- 16.2.Evidence-Based Treatment -- 16.2.1.Acute Mania -- 16.2.2.Acute Bipolar Depression -- 16.2.3.Maintenance Treatment -- 16.2.4.Treatment of Mixed Episodes -- 16.2.5.Treatment of Rapid Cycling Patients -- 16.2.6.Treatment of Special Conditions -- 16.2.7.Cautions for Pharmaceutical Treatment in BD Patients -- 16.2.8.Switching to the Opposite Pole -- References -- 17.1.General Background -- 17.2.Specific Psychotherapies and Psychosocial Interventions -- 17.2.1.Cognitive-Behavioural Therapy (CBT) -- 17.3.Psychoeducation -- 17.4.Interpersonal and Social Rhythm Therapy (IPSRT) -- 17.5.Family Intervention -- 17.6.Intensive Psychosocial Intervention -- 17.7.Cognitive Remediation and Functional Remediation -- 17.8.Mindfulness-Based Interventions -- References -- 18.1.Background -- 18.2.List of Existing Guidelines -- 18.3.Critical Review of the Most Important Guidelines -- 18.3.1.American Psychiatric Association Treatment Guidelines for BD -- 18.3.2.The Canadian Network for Mood and Anxiety Treatments and International Society on Bipolar Disorder Guidelines (CANMAT/ISBD) -- 18.3.3.The Texas Medication Algorithm Project (TMAP) for the Treatment of BD -- 18.3.4.The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of BD -- 18.3.5.British Association for Psychopharmacology (BAP) -- 18.3.6.The UK National Institute of Clinical Excellence (NICE) Treatment Guidelines for BD -- 18.4.Critical View of Treatment Guidelines for BD -- References -- 19.1.Gender -- 19.2.Suicidality -- 19.3.Paediatric BD -- 19.3.1.Epidemiology of Paediatric BD -- 19.3.2.Clinical Features of Paediatric BD -- 19.3.3.Aetiopathogenesis of Paediatric BD -- 19.3.4.Treatment of Paediatric BD -- 19.4.Geriatric BD -- 19.4.1.Epidemiology of Geriatric BD -- 19.4.2.Clinical Features of Geriatric BD -- 19.4.3.Neurobiology of Geriatric BD -- 19.4.4.Treatment of Geriatric BD -- References....”
Connect to electronic resource

Table of Contents “...Contents note continued: Low Back and Neck Pain Syndromes -- Neurological Disorders -- Alzheimer's Disease -- Parkinson's Disease -- Multiple Sclerosis -- Epilepsy or Seizures -- Brain and Spinal Cord Injury -- Visual Disorders -- Hearing Disorders -- Non-Communicable Diseases and the New Public Health -- Integrated Non-Communicable Disease Prevention and Control -- Summary -- Note -- Bibliography -- Recommended Reading -- Global Burden of Non-Communicable -- Diseases -- Social Determinants, Environment, and Economics of Non-Communicable Diseases -- Risk Factors, Health Promotion, and Prevention of Non-Communicable Diseases -- Smoking -- Diet, Physical Activity, and Obesity -- Infectious Diseases and Non-Communicable Diseases -- Hypertension and Cardiovascular Diseases -- Metabolic Syndrome, Diabetes Mellitus, and End-Stage Renal Disease -- Cancer -- Trauma, Violence, Injury, and Suicide -- Chronic Lung Disease -- Disabling Conditions -- 6.Family Health -- Introduction --...”

Table of Contents “...National Cancer Institute -- National Children's Study -- National Health and Nutrition Examination Survey (NHANES) -- National Health Interview Survey -- National Heart, Lung, and Blood Institute -- National Institute of Child Health and Human Development -- National Institute of Diabetes and Digestive and Kidney Diseases -- National Institute of Mental Health -- National Institute of Nursing Research -- National Institute on Aging -- National Institute on Alcohol Abuse and Alcoholism -- National Institutes of Health -- Natural Killer Cell Activity -- Needle Exchange Programs -- Negative Affect -- Negative Affectivity -- Negative Thoughts -- Nested Study -- Neuroendocrine Activation -- Neuroendocrine Theory of Aging -- Neurogenomics -- Neuroimaging -- Neuroimmunology -- Neuroimmunomodulation -- Neurological -- Neuromuscular Diseases -- Neuron -- Neuropeptide Y (NPY) -- Neuropsychology -- Neurotensin -- Neurotic Anger, Subcategory of Anger -- Neuroticism -- Neurotransmitter -- Nicotine -- Nicotine Patch -- Night-Shift Workers and Health -- Nitric Oxide Synthase (NOS) -- Nocebo and Nocebo Effect -- Nonexperimental Designs -- Non-REM Sleep -- Nonverbal Communication -- Norepinephrine/Noradrenaline -- Norms -- Nurses' Health Study -- Nutrition -- Nutrition Data System for Research (NDSR) -- Nutritional Supplements....”
Connect to electronic resource